ReviewCureus2025
An Emerging Paradigm for Safer and Faster Recovery: A Narrative Review on Opioid Sparing Anesthesia in Surgery.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regional Blocks in the Era of the Opioid Crisis: Evaluating Their Opioid-Sparing Effect.Cureus · 2026Review
- Evaluation of the Effect of Scalp Nerve Block on Bispectral Index Values During Skull Pinning; Prospective Observational Study.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid-free anesthesia (OFA) replaces opioid use with many non-opioid drugs, such as dexmedetomidine, lidocaine, esketamine, regional techniques, and enhanced recovery after surgery (ERAS)-aligned strategies to control pain while minimizing opioid-related adverse effects. Across surgical procedures, we conducted a narrative review of the literature, which showed that OFA is consistently associated with lower postoperative nausea and vomiting, faster recovery of gastrointestinal function, and reduced rescue opioid use, with similar post-anesthesia care unit (PACU) stay and pain scores in many trials. Pediatric and ambulatory settings also show fewer emetogenic symptoms and quicker readiness for discharge. However, evidence quality is mixed: several randomized trials and meta-analyses report meaningful reductions in PONV and opioid consumption but only modest or clinically marginal analgesic gains. Safety signals-particularly with α2-agonists like dexmedetomidine-include intraoperative hypotension/bradycardia and potential prolonged sedation, underscoring the need for careful dosing and patient selection. Contemporary guidance therefore favors opioid-sparing (minimizing rather than eliminating opioids) as a pragmatic interim goal while high-quality trials further define OFA's net benefit, optimal drug combinations, and perioperative extensions (e.g., postoperative low-dose infusions). Future work should refine protocols that de-emphasize routine lidocaine, titrate dexmedetomidine judiciously, and integrate targeted regional blocks to balance recovery benefits with hemodynamic safety, particularly in high-risk populations such as those with obesity or sleep apnea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.